Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Capital Expenditures (2022 - 2024)

Atara Biotherapeutics filings provide 3 years of Capital Expenditures readings, the most recent being $90000.0 for Q4 2024.

  • On a quarterly basis, Capital Expenditures fell 19.64% to $90000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was $90000.0, a 66.42% decrease, with the full-year FY2024 number at $246000.0, up 86.36% from a year prior.
  • Capital Expenditures hit $90000.0 in Q4 2024 for Atara Biotherapeutics, up from $29000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.2 million in Q1 2022 to a low of -$1.1 million in Q2 2022.
  • Median Capital Expenditures over the past 3 years was $29000.0 (2024), compared with a mean of $39909.1.
  • Biggest five-year swings in Capital Expenditures: surged 330.77% in 2023 and later plummeted 68.17% in 2024.
  • Atara Biotherapeutics' Capital Expenditures stood at $26000.0 in 2022, then surged by 330.77% to $112000.0 in 2023, then dropped by 19.64% to $90000.0 in 2024.
  • The last three reported values for Capital Expenditures were $90000.0 (Q4 2024), $29000.0 (Q2 2024), and $127000.0 (Q1 2024) per Business Quant data.